In a report released today, Carter Gould from Barclays maintained a Hold rating on Amgen (AMGN – Research Report), with a price target of $300.00. The company’s shares closed yesterday at $314.54.
Gould covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Biogen. According to TipRanks, Gould has an average return of 7.9% and a 55.79% success rate on recommended stocks.
In addition to Barclays, Amgen also received a Hold from Mizuho Securities’s Salim Syed in a report issued on May 9. However, on May 19, BMO Capital maintained a Buy rating on Amgen (NASDAQ: AMGN).
See today’s best-performing stocks on TipRanks >>
Based on Amgen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $7.45 billion and a GAAP net loss of $113 million. In comparison, last year the company earned a revenue of $6.11 billion and had a net profit of $2.84 billion
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amgen (AMGN) Company Description:
Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
Read More on AMGN:
- Amgen announces results of Phase 2a COURSE trial evaluating Tezspire
- U.S. FDA Approves Amgen’s (NASDAQ:AMGN) Imdelltra
- Amgen says FDA approves Imdelltra
- FDA grants accelerated approval for Amgen’s tarlatamab-dlle
- Dow Jones (DJIA) Dominates in May: Here’s Why the Trend Could Continue
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
